Shaq teams with Lilly to spotlight sleep apnea treatment with Zepbound
“Being prescribed Zepbound helped make a difference for me in my OSA treatment journey; I even lost some weight,” O’Neal said.
“Being prescribed Zepbound helped make a difference for me in my OSA treatment journey; I even lost some weight,” O’Neal said.
NACDS is advising chain pharmacy members on the upcoming launch of the CMS Medicare GLP-1 Bridge Program, a temporary demonstration that will provide eligible Medicare beneficiaries with access to certain medications beginning July 1.
The court unanimously ruled that Hikma's generic version of Amarin’s cardiovascular drug Vascepa (icosapent ethyl) does not infringe on the branded drug maker's patents.
The panel shared trends and tools to optimize biosimilar adoption to lower plan costs while supporting optimal health outcomes for members.
From Executive Fellow to senior leadership, McFeely has helped shape NACDS’ vision for the future of pharmacy-based care.
CVS Pharmacy uses robotics and automation at its Hainesport, N.J., center to improve inventory, speed store replenishment, and boost supply chain efficiency.
Prestigious recognition salutes career of transformational leadership.
Editorial spotlighting Alaska's HB 195 reinforces a national case for letting pharmacists practice at the top of their education.
By Todd Huseby is a partner at Kearney, a global management consulting firm. Michael Carr and Tonny Huang are principals at Kearney
Campaign puts focus on connection, presence and the power of showing up fully.
Schoenberg, is a physician, entrepreneur, and pioneer of digital healthcare, having co-founded and led Amwell — a leading telehealth company — for nearly two decades.
Danny Sanchez, CEO of EmpiRx Health, joins an expert panel focused on the role of pharmacy benefit managers as value-based partners in more accountable, patient-focused pharmacy care.
“We’re becoming high-tech, high-touch care providers, delivering proactive, personalized and preventative care where patients need it most.”
The company continues to launch innovative digital offerings to help members access care, as part of its $20 billion technology investment, announced in 2025.
The presentations come as competition intensifies among drugmakers racing to develop more effective therapies for obesity and diabetes.